

12 July 2016 EMA/482832/2016 Information Management Division

## Monthly statistics report: June 2016

Medicinal products for human use (cumulative figures for the year to date)

This document provides current information related to the volume and evaluation of marketing authorisation and post-authorisation applications for medicinal products for human use received by the European Medicines Agency.

The purpose is only to provide ongoing factual information. Commentaries and analysis are provided in the Agency's annual reports.

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact



An agency of the European Union

 $\odot$  European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged.


	2013		2014		2015		<b>2016</b> <sup>+</sup>	
Γ	Started	Finalised	Started	Finalised	Started	Finalised	Started	Finalised
Non-orphan medicinal products								
New products	48	46	37	42	36	41	17	14
Advanced-therapy medicinal products	0	2	1	0	0	1	0	0
Paediatric-use (PUMA) products	1	0	0	1	1	0	0	1
Well-established use, abridged, hybrid and informed consent products	6	4	12	15	8	7	1	4
Generic products	5	16	25	6	28	25	10	9
Similar biological products	1	4	3	3	12	2	3	1
Sub-total product applications	61	72	78	67	85	76	31	29
Orphan medicinal products <sup>◊</sup>								
New products	16	14	20	17	24	20	10	8
Advanced-therapy medicinal products	2	0	1	1	1	1	1	2
Total product applications	79	86	99	85	110	97	42	39

### **Table 1.** Pre-authorisation: Marketing-authorisation applications<sup>\*</sup>

<sup>\*</sup> Finalised applications exclude applications withdrawn prior to opinion.

<sup>†</sup> Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year.

 $^{\diamond}$  These figures reflect the orphan status of the medicinal products at the time of the CHMP opinion. EMA's Committee for Orphan Medicinal Products (COMP) then assesses whether the orphan designation should be maintained.



# Marketing authorisation application evaluations started by type of application

New medicinal products (non-orphan) 
 Orphan medicinal products 
 Similar biological products 
 Generics, hybrid products, etc.

 $^\dagger$  Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year.


	2013	2014	2015	<b>2016</b> <sup>†</sup>
Positive opinions	79	81	93	37
Opinions recommending conditional ** marketing authorisation	4	4	3	3
Opinions under exceptional ** circumstances	3	1	3	0
Negative opinions	7	4	4	2
Opinions after accelerated assessment**	5	7	5	4
Applications withdrawn prior to opinion	8	6	5	6
Re-examinations requested	10	5	1	2
Re-examination - Positive opinions	3	1	0	0

**Table 2.** Pre-authorisation: Outcome of the evaluation of marketing authorisation applications\*

\* Applicants can request a re-examination. The first four rows present the outcome of the evaluation before a re-examination (or a re-consideration). The final row shows the number of changes from a negative to a positive opinion following a re-examination or a re-consideration.

 $^{**}$ Included in the figures for positive opinions.

<sup>†</sup> Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year.



### Pre-authorisation: Outcome of the evaluation of marketing authorisation applications

<sup>†</sup> Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year.

#### Table 3. Scientific services

	2013		2014		2015		<b>2016</b> <sup>†</sup>	
Γ	Started	Finalised	Started	Finalised	Started	Finalised	Started	Finalised
Compassionate-use opinions	2	2	1	1	0	0	0	0
Art. 58 (WHO) scientific opinions	1	1	1	1	1	1	0	1
Opinions on ancillary medicinal substances in medical devices*	3	1	0	1	1	1	0	0
Plasma master file (includes initial certification, variations and annual re-certification)	19	13	16	16	17	19	7	14


\* Consultation in accordance with Council Directive 93/42/EEC concerning medical devices as amended by Directive 2000/70/EC as regards medical devices incorporating stable derivates of human blood or plasma and Directive 2001/14/EC.

<sup>†</sup> Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year.

	2013		2014		2015		<b>2016</b> <sup>+</sup>	
Γ	Started	Started	Started	Finalised	Started	Finalised	Started	Finalised
Type IA variations	2,922	2,886	2,969	2,854	2,829	2,849	1,551	1,467
Type IB variations	1,958	1,597	1,886	1,986	1,954	1,838	951	1,042
Type II variations	961	946	1,151	1,103	1,168	1,097	452	546
Extensions of marketing authorisation	16	18	16	15	14	15	11	8
Annual reassessments	18	16	18	18	16	20	7	12
Renewals*	98	77	100	121	71	75	52	44

\* Includes renewals of conditional marketing authorisations.

 $^{\dagger}\,$  Figures for the current year are cumulative, year to date. Figures for preceding years are totals for the year.



Post-authorisation: Variations, renewals and annual reassessments